Breakthrough pre-clinical, research findings to be released show therapeutic advancements on the data-driven evolution of psychedelic psilocybin molecule TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, will host an in-person and virtual research and development (“R&D”)…


Previous articlePT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure
Next articleBraxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial